COVID-19 mRNA vaccine is not detected in human milk
Golan, Y.; Prahl, M.; Cassidy, A.; Lin, C. Y.; Ahituv, N.; Flaherman, V. J.; Gaw, S. L.
Show abstract
Several countries have recently approved the use of mRNA vaccines against COVID-19 under an emergency use authorization. However, no pregnant or lactating individuals were included in the Phase 3 clinical trials of these vaccines despite belonging to a group at high risk for severe complications of COVID-19 infection. We show here that the mRNA from anti-COVID BNT162b2 (Pfizer) and mRNA-1273 (Moderna) vaccines is not detected in human breast milk samples collected 4-48 hours post-vaccine. These results strengthen the recommendation of ABM and WHO that lactating individuals who receive the anti-COVID-19 mRNA-based vaccine should continue to breastfeed their infants uninterrupted.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Quantification of specific antibodies against SARS-CoV-2 in breast milk of lactating women vaccinated with an mRNA vaccine 96%
- Safety of the BNT162b2 mRNA COVID-19 Vaccine in Children below 5 Years (CoVacU5) – an Investigator-Initiated Retrospective Cohort Study 89%
- Durability of the immune response to a third BNT162b2 dose; five months follow-up 87%
Similar papers in this journal
- Human Milk Antibodies Elicited by BNT162b2 Vaccination have reduced activity against SARS-CoV-2 Variants of Concern 92%
- Broad Cross-reactive IgA and IgG Against Human Coronaviruses in Milk Induced by COVID-19 Vaccination and Infection 91%
- Tracking Immunity: Increased number of COVID-19 boosters increases the longevity of anti-RBD and anti-RBD neutralizing antibodies 90%
Similar papers in this journal
Similar papers in this journal
- Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination 92%
- Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice 90%
- Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals 89%
Similar papers in this journal
- Protecting against Respiratory Syncytial Virus: An online questionnaire study exploring UK parents’ acceptability of vaccination in pregnancy or monoclonal antibody administration for infants 89%
- Performance of RT-PCR on saliva specimens compared to nasopharyngeal swabs for the detection of SARS-CoV-2 in children: A prospective comparative clinical trial 88%
- Back to school: use of Dried Blood Spot for the detection of SARS-CoV-2-specific immunoglobulin G (IgG) among schoolchildren in Milan, Italy. 87%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.